Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

Abstract: Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

Abstract: A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment f

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Techniques are provided for replacing image assays using real world data and real word evidence RNA-seq analysis for assessing biologic pathways for identifying molecular subtypes. Systems of a methods diagnose HER2 status for a patient, by identifying discordant HER2 status result between the HER2 status from immunohistochemistry (IHC) and the HER2 status from fluorescence in-situ hybridization (FISH) and diagnosing HER2 status based gene expression data.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Various embodiments provide interfaces to access genomic testing information and incorporate it into daily physician practice. According to one aspect, a graph-based data model is used that may be used to organizes and revise precision medicine knowledge. In one example structure, gene states are abstracted into alteration groups, where alteration groups are built using reverse engineering actionable information and storing that information within the graph-based data structure. Volumes of genomic alterations and associated information (e.g., journal articles, clinical trial information, therapies, etc.) are analyzed and synthesized into actionable information items viewable on an alteration system in a graph-based data format. According to one embodiment, the system can be configured to focus practitioners on discrete portions of the alteration information on which they can act.

Abstract: Techniques for analysis of gene expression data contained in real world data and real word evidence for assessing biologic pathways for identifying molecular subtypes are provided. Systems and methods include, for a plurality of biological pathways, determining a pathway score using gene expression data and determining of summary score for the plurality of biological pathways. That summary score may be compared to one or more enrichment scores each associated with a pre-determined molecular subtype. A molecular subtype is determined based on that comparison. Various heuristics may be applied to filter pathways before summary scoring.

Abstract: Techniques are provided for replacing image assays using real world data and real word evidence RNA-seq analysis for assessing biologic pathways for identifying molecular subtypes. Systems of a methods diagnose HER2 status for a patient, by identifying discordant HER2 status result between the HER2 status from immunohistochemistry (IHC) and the HER2 status from fluorescence in-situ hybridization (FISH) and diagnosing HER2 status based gene expression data.

Abstract: Techniques for analysis of gene expression data contained in real world data and real word evidence for assessing biologic pathways for identifying molecular subtypes are provided. Systems and methods include, for a plurality of biological pathways, determining a pathway score using gene expression data and determining of summary score for the plurality of biological pathways. That summary score may be compared to one or more enrichment scores each associated with a pre-determined molecular subtype. A molecular subtype is determined based on that comparison. Various heuristics may be applied to filter pathways before summary scoring.

Abstract: Various embodiments provide interfaces to access genomic testing information and incorporate it into daily physician practice. In some embodiments, presentation of genomic alteration data is simplified and/or coupled with contextual applications. Volumes of genomic alterations and associated information (e.g., journal articles, clinical trial information, therapies, etc.) are analyzed and synthesized into actionable information items viewable on an alteration system. According to one embodiment, the system can be configured to focus practitioners on discrete portions of the alteration information on which they can act. According to other aspects, curated information is provided on the system to enable practitioners to make informed decisions regarding the implications of the presence of specific genomic alterations.

Abstract: A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment f

Abstract: A system for managing genomic information includes a processor to collect and store biomarker data, receive and store patient-specific pathology information, generate a graph-based data structure of complex data elements arranged into a walkable graph representation that includes at least one of a disease alteration group association (DAGA) element representing a relationship between a disease and an alteration group (AG), at least one of a disease therapy association (DTA) element representing a relationship between a disease and a therapy for treating the disease, and a therapy genomic effect (TGE) element representing a relationship between a gene and a known effect of a therapy on the gene. The processor follows links in the walkable graph representation to determine at least one inferred path, generates inferential matches to actionable items based on an accumulated trust score of the at least one inferred path, and determines a treatment decision for a cancer patient.

Abstract: Workstations including a base, a basin supported on the base for processing material into components, a mounting bracket attached to the basin, and a container with an opening for collecting a desired component of the material processed in the basin, the container being removably attached to the mounting bracket in a position where the opening is adjacent to the basin.

Abstract: In one embodiment, a drying rack system includes a frame including horizontal members and vertical members, an array of brackets supported by the frame, and a plurality of clamping hangers supported by the brackets. A first clamping hanger of the plurality of clamping hangers may include a pair of opposing clamping jaws configured to compress against each other, and a hinge securing the clamping jaws together proximal one end of the first clamping jaw.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: Novel mutant ESR1 molecules and uses are disclosed.

Abstract: A simplified method for production of a commercial supply liquefied natural gas (LNG) supplied in a pressurized vessel includes taking a supply of natural gas including contaminants from a stranded well or from a pipe line and extracting from the supply gas water vapor and CO2 in a fixed bed absorption system. In a first stage the supply gas is separated into first and second streams where the first stream contains all the cold energy available from the feed stream and sufficient of the contaminants are removed to meet a product specification for the composition of the LNG supply. In a second stage the first stream is liquefied by the available cool energy for commercial pressurized supply container The second stream contains natural gas which is as much as 75% of the feed stream together with substantially all the contaminants and is used as a natural gas supply.